케이팜

비상장계속사업자

KPHARM

이상도

Investment Review Report

Auto-filled from disclosures & public data + AI-drafted analysis. Edit, then export to PDF/DOCX.

Editor

1.Deal Terms

2.Valuation / Exit Assumptions

Exit Scenarios100M KRW

3.Fund Eligibility

Fund mandate eligibility — no data, enter manually

Enter fund mandate requirements and applicability (Y/N) to include a table in the report.

4.Capital Changes

Not in DART — enter capital-raise history manually

Enter capital changes such as founding capital and paid-in increases.

5.Stock Options

Enter manually

Enter stock option grant history.

6.Investment Highlights

AI draft — editable

Click 'Generate AI draft' to populate data-grounded investment highlights.

7.Investment Risks

AI draft — editable

Risks are populated after 'Generate AI draft'.

8.Market Analysis

AI draft — editable

9.Business Analysis

AI draft — editable

10.Conclusion (Investment Opinion)

AI draft — editable

11.P&L Projection

Analyst estimates, manual entry (100M KRW). Generates a trend chart & table.

Enter projected revenue / op. profit / net income (100M KRW) by year to add a trend chart and table.
Preview— the document below is saved as PDF/DOCX

Investment Review Report

케이팜

Business Reg. No. 8098701445 · CEO 이상도

I.Investment Overview

Target케이팜 (8098701445)
Investment
Post-deal stake
ValuationPre — / Post —

II.Investment Highlights

No investment highlights written yet.

III.Investment Risks

No risks written yet.

IV.Company Profile

회사명케이팜
영문명KPHARM
대표자이상도
사업자등록번호8098701445
법인등록번호2842110092199
설립일2019.06.18

V.Financial Summary

Per DART disclosure · in 억/만원 (KRW)

Financial trend (100M KRW)

매출액100M KRW607.92021661.22022776.3202388820241,036.52025
영업이익100M KRW28.5202131.9202234.8202336202445.52025
순이익100M KRW22.7202125.4202227.9202327.8202436.32025
Item20252024202320222021
자산총계251.8억원186.8억원156.5억원144.5억원133.7억원
부채총계196.9억원143.6억원116.6억원110억원104.2억원
자본총계55억원43.1억원39.9억원34.4억원29.5억원
매출액1,036.5억원888억원776.3억원661.2억원607.9억원
영업이익45.5억원36억원34.8억원31.9억원28.5억원
순이익36.3억원27.8억원27.9억원25.4억원22.7억원

VI.Financial Ratios

FY2025 basis

4.39%

영업이익률

3.5%

순이익률

14.42%

ROA

66.07%

ROE

358.15%

부채비율

21.83%

자기자본비율

VII.Valuation & Exit Plan

Exit valuation
Holding period5y
Enter exit assumptions (investment, stake, exit valuation, period) to see MOIC·IRR.

This report compiles disclosure & public data and AI-drafts some sections as a research aid. It is not investment advice; the user bears final responsibility for facts and investment decisions.

케이팜 투심보고서 | Alpha Lenz